(Q33425781)

26 July 2017

title

Ruxolitinib: A Review in Polycythaemia Vera (English)

1 reference

26 July 2017

1 reference

1

Kate McKeage

1 reference

26 July 2017

publication date

11 September 2015

1 reference

26 July 2017

1 reference

26 July 2017

volume

75

1 reference

26 July 2017

issue

15

1 reference

26 July 2017

page(s)

1773-1781

1 reference

Novel and emerging therapies for the treatment of polycythemia vera

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Therapy for myeloproliferative neoplasms: when, which agent, and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Myeloproliferative neoplasms and thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Mechanisms of thrombogenesis in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

How I treat polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Ruxolitinib: a review of its use in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Ruxolitinib: in the treatment of myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

The role of the thymus in T-cell immune reconstitution after umbilical cord blood transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Ruxolitinib for the treatment of patients with polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

The future of JAK inhibition in myelofibrosis and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0470-2

Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.).

21 January 2018

1 reference

12 December 2020

Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera

1 reference

12 December 2020

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

1 reference

12 December 2020

Epidemiology of myeloproliferative neoplasms in the United States

1 reference

12 December 2020

10.1007/S40265-015-0470-2

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1006273175

0 references

1 reference